Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, SomaLogic Sign Custom Microarray Supply Agreement

NEW YORK (GenomeWeb) – Agilent Technologies and biotechnology company SomaLogic announced today that they have signed a multi-year supply agreement for Agilent to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.

Specific terms of the deal were not disclosed.

The SomaScan assay is a protein measurement platform with applications in basic and clinical research, diagnostics, and pharmaceutical discovery and development, the companies said. It solves the problem of protein measurement using a DNA measurement solution. The customized Agilent microarray will be used as part of a step to enable the assay to detect and measure 5,000 proteins accurately and reproducibly from a small volume of biological sample.

"Agilent and SomaLogic have developed a mutually rewarding partnership over the years, and we are pleased that they will continue to leverage our microarray platform as they scale up their business," Sam Raha, president of Agilent's diagnostics and genomics group, said in a statement. "Agilent's microarray platform has demonstrated superiority for measurement of DNA and RNA at scale and it is exciting to see how SomaLogic is creatively applying this capability to measure thousands of proteins in a single assay."

SomaLogic CEO Roy Smythe also noted that the company has analyzed more than 300,000 human samples to date as it has worked to build the SomaScan platform, and that Agilent's custom microarrays will help the firm as it scales into health, wellness, and disease monitoring applications for the technology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.